IMS Health has appointed a new general manager for the UK, Ireland & South Africa.
Mike Sanvoisin will be responsible for all aspects of the company’s local market business operations.
Sanvoisin succeeds Seyed Mortazavi, who has been appointed EMEA president.
Looking forward to his new role, Mr Sanvoisin said: “At the start of this year we embarked on a three year plan to look at the way IMS measures the evolving pharmaceutical market and delivers services to our customers. This plan will allow IMS to deliver more thought leadership programmes through our Management Consulting team in areas like Product Strategy, Launch Excellence and New Commercial Models.
“IMS is increasingly working with multiple stakeholders and frequently find ourselves in the centre of healthcare conversations such as our inclusion as expert advisor to the Department of Health, for the recent report on ‘Extent and Causes of International Variation in Drug Usage’.
“I’m proud of IMS’ participation in these discussions as I believe our expertise can add considerable value to the changing healthcare environment for both the Department of Health and our pharmaceutical clients.”